中国药学杂志
    
           首页  |  期刊介绍  |  编 委 会  |  投稿指南  |  期刊订阅  |  广告服务  |  会议信息  |  联系我们  | 
�й�ҩѧ��־ 2013, Vol. 48 Issue (6) :406-409    DOI: 10.11669/cpj.2013.06.002
�� �� ����Ŀ¼ | ����Ŀ¼ | ������� | �߼����� << [an error occurred while processing this directive] | [an error occurred while processing this directive] >>
��������ø����ֳ�D������-γ��ص�ҩ���з���չ
̷����1,ʱ����1,��ֲ��1,��Ϊ��1,������2*
1.���ҩ���о�Ժ,�������ҩ����뷢���ص�ʵ����,��� 300193;2.���ҩ���о�Ժ,ҩЧѧ��ҩ������ѧʡ�����������ص�ʵ����, ��� 300193

Download: PDF (661KB)   HTML (1KB)   Export: BibTeX or EndNote (RIS)      Supporting Info
ժҪ Ŀ�� �����������Թ�������ø����ֳ�D������-γ (peroxisome proliferators activated receptor γ, PPAR-γ)Ϊ�е��ҩ���з���״���չ������ �Խ����й��Թ�������ø����ֳ�D������Ϊ�е��ҩ���о�������׽��в��ġ��ռ�,ͨ�����������ɺ��ۺϽ����������������� ��������ø����ֳ�D������-γ�������޸���ͪ��������ͪ�������Եؽ���Ѫ�Ǻ���ǿ�ȵ��������Ե�����,���޸���ͪ������Ѫ�ܷ���,������ͪ�ɽ������򲡻�����Ѫ�ܷ��ա���Ϊ��ȫ��Ч������ѡ���Թ�������ø����ֳ�D������-γ���ڼ��ǹ�������ø����ֳ�D������-γ���ҩ���з�����������Ҫ����
Service
�ѱ����Ƽ�������
�����ҵ����
�������ù�����
Email Alert
RSS
�����������
̷����
ʱ����
��ֲ��
����
������*
�ؼ����� ��������ø����ֳ�D������-&gamma   ����    �޸���ͪ    ��Ѫ�ܷ���     
Abstract��
Keywords��   
�ո�����: 2012-11-03;
��������:

“�ش���ҩ����”�Ƽ��ش�ר�2011ZX09401-009��

ͨѶ���� ������,��,����,�о�Ա,��ʿ����ʦ �о�����ҩ��ѧ Tel/Fax����022��23006950 E-mail��tangld@tjipr.com��������ø����ֳ�D������-����ص�ҩ���з���չ ̷����1     Email: tangld@tjipr.com
���߼��: ̷����,��,���о�Ա �о�����ҩ��ѧ ͨѶ���ߣ�������,��,����,�о�Ա,��ʿ����ʦ �о�����ҩ��ѧ Tel/Fax����022��23006950 E-mail��tangld@tjipr.com
���ñ���:   
̷����, ʱ����, ��ֲ���� .��������ø����ֳ�D������-γ��ص�ҩ���з���չ[J]  �й�ҩѧ��־, 2013,V48(6): 406-409
TAN Chu-Bing-, SHI Li-Li-, ZHOU Zhi-Xing- etc .[J]  Chinese Pharmaceutical Journal, 2013,V48(6): 406-409
��
[1] MICHALIK L,AUWERX J,BERGER J P,et al. International union of pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev,2006,58(4):726-741.
[2] CIUDIN A,HERNANDEZ C,SIMO R. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Curr Top Med Chem,2012,12(6):585-604.
[3] ROSEN C J. Revisiting the rosiglitazone story--lessons learned. N Engl J Med,2010,363(9):803-806.
[4] KAUL S,BOLGER A F,HERRINGTON D,et al. Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation,2010,121(16):1868-1877.
[5] NISSEN S E,WOLSKI K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med,2007,356(24):2457-2471.
[6] LUCONI M,CANTINI G,SERIO M. Peroxisome proliferator-activated receptor gamma (PPARgamma): Is the genomic activity the only answer. Steroids,2010,75(8-9):585-594.
[7] ROBINSON E,GRIEVE D J. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease. Pharmacol Ther,2009,122(3):246-263.
[8] SZANTO A,NAGY L. The many faces of PPARgamma: Anti-inflammatory by any means?. Immunobiology,2008,213(9-10):789-803.
[9] YESSOUFOU A,WAHLI W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly,2010,140:w13071. doi: 10.4414/smw.2010.13071.
[10] LEHRKE M,LAZAR M A. The many faces of PPARgamma. Cell,2005,123(6):993-999.
[11] CANTINI G,LOMBARDI A,BORGOGNI E,et al. Peroxisome-proliferator-activated receptor gamma (PPARgamma) is required for modulating endothelial inflammatory response through a nongenomic mechanism. Eur J Cell Biol,2010,89(9):645-653.
[12] LOMBARDI A,CANTINI G,MELLO T,et al. Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium. Eur J Cell Biol,2009,88(12):731-742.
[13] MORAES L A,SPYRIDON M,KAISER W J,et al. Non-genomic effects of PPARgamma ligands: Inhibition of GPVI-stimulated platelet activation. J Thromb Haemost,2010,8(3):577-587.
[14] BISHOP-BAILEY D.The platelet as a model system for the acute actions of nuclear receptors. Steroids,2010,75(8-9):570-575.
[15] VILLACORTA L,SCHOPFER F J,ZHANG J,et al. PPARgamma and its ligands: Therapeutic implications in cardiovascular disease. Clin Sci (Lond),2009,116(3):205-218.
[16] KUMMER M P,HENEKA M T. PPARs in Alzheimer's Disease. PPAR Res,2008,2008:403896. http://www.hindawi.com/journals/ppar/2008/403896.
[17] MICHALIK L,WAHLI W. PPARs Mediate Lipid Signaling in Inflammation and Cancer. PPAR Res,2008,2008:134059. http://www.hindawi.com/journals/ppar/2008/ 134059.
[18] MCTIGUE D M. Potential Therapeutic Targets for PPARgamma after Spinal Cord Injury. PPAR Res,2008,2008:517162.http://www.hindawi.com/journals/ppar/2008/ 517162.
[19] ROBBINS M E,LINARD C,PANIGRAHY D. PPARs and Anticancer Therapies. PPAR Res,2010,2010:536415. http://www.hindawi.com/journals/ppar/2010/536415.
[20] ZHANG H A,DU G H. Advances in drug research of prevention and treatment of kidney disease target PPAR. Chin Pharm J(�й�ҩѧ��־),2010,45(7):481-485.
[21] CHO N,MOMOSE Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: From the discovery to recent progress. Curr Top Med Chem,2008,8(17):1483-1507.
[22] PALEE S,CHATTIPAKORN S,PHROMMINTIKUL A,et al. PPARgamma activator,rosiglitazone: Is it beneficial or harmful to the cardiovascular system. World J Cardiol,2011,3(5):144-152.
[23] ROGUE A,SPIRE C,BRUN M,et al. Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. PPAR Res,2010,2010:325183. http://www.hindawi.com/journals/ppar/2010/325183.
[24] NICHOLLS S J,UNO K. Peroxisome proliferator-activated receptor (PPAR-alpha/gamma) agonists as a potential target to reduce cardiovascular risk in diabetes. Diab Vasc Dis Res,2012,9��2��:89-94.
[25] ZHANG F,LAVAN B E,GREGOIRE F M. Selective Modulators of PPAR-gamma Activity: Molecular Aspects Related to Obesity and Side-Effects. PPAR Res,2007,2007:32696. http://www.hindawi.com/journals/ppar/2007/032696.
[26] GELMAN L,FEIGE J N,DESVERGNE B. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes. Biochim Biophys Acta,2007,1771(8):1094-1107.
[27] CHOI J H,BANKS A S,ESTALL J L,et al. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5. Nature,2010,466(7305):451-456.
[28] CAIN C,WRITER S. Resolving the PPARγ paradox. SciBX,2010,3(31):1-3. http://www. nature. com/scibx/journal/v3/n31/pdf/scibx. 2010. 940. pdf.
[29] JONES D. Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov,2010,9(9):668-669.
[30] RUBENSTRUNK A,HANF R,HUM D W,et al. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta,2007,1771(8):1065-1081.
[31] HIGGINS L S,DEPAOLI A M. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr,2010,91(1):267-272.
[32] SHEARER B G,BILLIN A N. The next generation of PPAR drugs: Do we have the tools to find them?. Biochim Biophys Acta,2007,1771(8):1082-1093.
[33] DUNN F L,HIGGINS L S,FREDRICKSON J,et al. Selective modulation of PPARgamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. J Diabetes Complications,2011,25(3):151-158.
[34] GREGOIRE F M,ZHANG F,CLARKE H J,et al. MBX-102/JNJ39659100,a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. Mol Endocrinol,2009,23(7):975-988.
[35] CHANDALIA A,CLARKE H J,CLEMENS L E,et al. MBX-102/JNJ39659100,a Novel Non-TZD Selective Partial PPAR-gamma Agonist Lowers Triglyceride Independently of PPAR-alpha Activation. PPAR Res,2009,2009:706852. http://www. hindawi. com/ journals/ppar/2009/706852/
[36] BALAKUMAR P,ROSE M,GANTI S S,et al. PPAR dual agonists: Are they opening Pandora's Box. Pharmacol Res,2007,56(2):91-98.
[37] TENENBAUM A,MOTRO M,FISMAN E Z. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol,2005,4:14 . http://www.cardiab.com/content/4/1/14.
[38] DESOUZA C,FONSECA V. Therapeutic targets to reduce cardiovascular disease in type 2 diabetes. Nat Rev Drug Discov,2009,8(5):361-367.
[1] ������,����ƽ*.������ͪ�����򲡴���������ŵ��ױ���Ӱ��[J]. �й�ҩѧ��־, 2013,48(6): 441-445
[2] ����ũ;�⾧;��ӱ��;�ٺ���;���;�벨;�ﶬ÷;����֥;�����;�ŷ�.�й����г���2�����򲡽���ҩ�����ƻ���ҩ��ʹ�õ������[J]. �й�ҩѧ��־, 2012,22(9): 736-738
[3] л��÷��������������.������ͪ������ģ��С��Ľ�Ѫ�����ü�������о�[J]. �й�ҩѧ��־, 2012,47(23): 1899-1904
[4] �����������ޣ��˾��ϣ���С����������.��ܺຶ������������յ�2�����򲡴����������������ü�����[J]. �й�ҩѧ��־, 2012,47(22): 1807-1812
[5] ���ķң� �����ᣬ �־����� ��־»*���췼�� ��ӱ.�޸���ͪ�Զ�������Ӳ���ð׽���-18������ϸ����������-1�����ʽ�������ø-9����Ӱ��[J]. �й�ҩѧ��־, 2012,47(20): 1621-1624
[6] ���������ᣬ����쿣�������.���ڹ���1��6-��������ø�ṹ��Ƶ�ҩ���о���չ[J]. �й�ҩѧ��־, 2012,47(15): 1189-1193
[7] ��������������С��.���Ƣ���������ҩ——������͡[J]. �й�ҩѧ��־, 2012,47(14): 1181-1182
[8] ����ϼ��������*�����.����θ�ĺ��ȸ�Ѫ��������1���о���չ[J]. �й�ҩѧ��־, 2012,47(13): 1025-1028
[9] ����.�ڷ�����ҩ���ϸʾ��ȵ�������2�����򲡵��ٴ�����[J]. �й�ҩѧ��־, 2012,47(12): 1014-
[10] ������.ά����Dȱ�����ٴ�ҩ��ѧ����ض�ͯ�ڼ��������о���չ[J]. �й�ҩѧ��־, 2012,47(10): 753-757
[11] ��Ȼ ������ ��С��.��������ҩ�������ȸ�Ѫ������������������³��[J]. �й�ҩѧ��־, 2011,46(8): 637-639
[12] ���� ������.����³����������2�������ٴ��о���״[J]. �й�ҩѧ��־, 2011,46(21): 1685-1687
[13] ���۷� ������ ������ ��ӯӯ.���ĸ����ܻ�ͪ�����򲡴���Ѫ�Ǽ�����Ӧ����Ӱ��[J]. �й�ҩѧ��־, 2011,46(20): 1570-1573
[14] ������ ������ ����ʤ ������ ������.����ض����򲡴�������ѪС�巴Ӧ����1����������õ��о�[J]. �й�ҩѧ��־, 2011,46(17): 1326-1329
[15] ��ƽ ���� ���� ���� ������ �ձ��� �����.����˫�Ҹ�����ຸ����Ƽ�����2�����򲡵Ķ����������˫ä�ٴ�����[J]. �й�ҩѧ��־, 2011,46(17): 1362-1365
Copyright 2010 by �й�ҩѧ��־